Emerging Prognostic Biomarkers in Urothelial Carcinoma
|
|
- Nelson Clark
- 5 years ago
- Views:
Transcription
1 Emerging Prognostic Biomarkers in Urothelial Carcinoma George J. Netto, M.D. Departments of Pathology, Oncology & Urology Johns Hopkins University Baltimore, MD USA
2 Overview Current Clinicopathologic Prognostic Parameters Molecular Pathways of Oncogenesis Emerging Prognostic Biomarkers Targets of Therapy
3 Bladder Carcinoma Epidemiologic Features In USA: 72,570 new cases 15,210 deaths in ,000 new cases worldwide Peak incidence: sixth decade. Male/Female: almost 3/1 4th most common in M and 12th most common in F Highest incidences in: Western Europe, N. America and Australia.
4 UrCa Disease Costs and Management Opportunities Major health cost burden per patient: - Frequent cystoscopy, high rate of recurrence etc - $ 4 Billion per year in USA alone; largest cost per pt for any type of tumor Unique amenability to applying molecular detection methods (e.g. UroVysion FISH, FGFR3 mutation) and molecular Rx delivery to target
5 Urothelial Carcinoma (UrCa) Two Phenotypes? Superficial non-muscle invasive UrCa (NMI-BC) : 70-80% Majority of UrCa (60-70%) present as non-invasive (pta) tumors at time of first Dx 50% will recur as non-invasive tumors and only 5-10% of will progress Mainstay of Rx: TURB +/- Intravesical Chemotherapy and Immune therapy BCG Muscle Invasive UrCa (MI-BC): 20-30% 15 % of MI UrCa have history of prior Superficial UrCa 80-90% are primary Muscle invasive UrCa Practically all are high grade Despite aggressive Rx (Cystectomy +/- Chemotherapy) <50% overall survival
6 Bladder Urothelial Carcinoma Two Divergent Molecular Pathways Superficial TCC H-RAS/FGFR3/mTOR Normal Urothelium Urothelial Hyperplasia PUNLMP Low Grade Papillary UrCa Falt CIS High Grade Papillary UrCa Invasive UrCa Muscle Inv TCC P53/RB
7 Clinico-Pathologic Prognostic Factors
8 Superficial Urothelial Carcinoma (Non-Muscle Invasive UrCa) pta/pt1 Pathologic Prognosticators WHO/ISUP 2004 Grade pt: pta vs pt1 Depth of Lamina propria Invasion: pt1a,b,c CIS, Prostatic duct involvement LVI? Size: >5 cm Multifocality/Extent: ureter, upper tract and urethral involvement Failed Intravesical Rx /Recurrence within 6 month Duration of Disease Soloway et al J Urol 2002 O Donnell et al Sem Oncol 2007
9 Non-Invasive Urothelial Carcinoma Recurrence/Progression WHO/ISUP Grade: Urothelial Papilloma: lowest risk of recurrence & no progression PUNLMP: 35% (25-47%) risk of recurrence, 4% risk of progression, 1% DOD LG UrCa: 50% (30-76%) recurrence rate, 10% progress, 5% DOD HG UrCa: most frequent recurrence rate ( 50-69%), 25-65% progress Flat CIS is an aggressive disease Chaux A et al Hum Pathol 2011 Lee et al Hun Pathol 2011 Ledbret et al J Urol 2000 Lopez-Beltran et al Eur Urol 2004
10 Sylvester et al. Eur Urol pts from 7 EORTC trials Predictive Model Parameters: Number of Tumors Tumor Size : 3 cm Prior Recurrence Rate: 1 Rec/yr pt CIS WHO grade
11 Sylvester et al. Eur Urol 2006
12 Stein et al J Clin Oncol pts uniformly Rx: Radical Cystectomy+LN ± Adj Chemo radiation 10.2 yr median F/U DFS 68% at 5yr and 60% at 10 yrs ptnm significant predictor (OC vs Non OC) in term of DFS and OS - OC LN neg group: 85% DFS at 5yr - Non OC LN neg group: 58% DFS at 5yr - LN positive group: 35% DFS at 5yr Stage Sub-grouping within OC and Non OC was not significant predictor of DFS or OS DFS OS
13 Urinary Bladder Urothelial Ca Molecular Pathways
14 Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% Normal Urothelium ~15% 20-30% ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis Netto, G. J. Nature Rev. Urol
15 9q-/9p- Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% Normal Urothelium ~15% 20-30% 9q-/9p- ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis Netto, G. J. Nature Rev. Urol
16 Lindgren et al PLoS 2012 Bladder Urothelial Ca Chromosomal Alterations
17 Bladder Urothelial Carcinoma Chromosomal Aberrations Chromosome 9: Genetic losses in Chromosome 9 are early events in both Superficial and MI-BCa LOH analysis, CGH and array CGH consistently detected deletions in both arms of Ch 9 (up to 80-90%) Potential TSG Loci: - 9p21: CDKN2A (encodes p16 and p14); deleted in up to 50% of UrCa - 9q34: TSC1
18 Bladder Urothelial Carcinoma Chromosomal Aberrations Chromosomal Gains: 3q,7p,17q gains 17q gains: HER2 amplification; TOPO2A Diagnostic Application: Numerical Ch 3, 7, 17 are exploited in UroVysion FISH assay (in addition to loss of 9p21)
19 Moonen et al Eur Urol 2007 Red: Ch3 Green: Ch 7 Blue: Ch 17 Gold: 9p21 UroVysion positivity (i) at least 4 cells with gain of more than 1 chromosome of chrom 3,7,17 and/or (ii) at least 12 cells with heterozygous or homozygous deletion of 9p21
20 Skacel et al J Urol 2003: 120 urine cytology (instrumented and voided) All with concurrent TURBT (82 UrCa + 38 negative) Overall: Sensitivity 85% Specificity of 97% FISH sensitivity in Cytology Groups: 100% (suspicious Cyto) 89% (Atypical Cyto) 60% (Negative Cyto) 8/9 FISH positive pts with originally negative bx had subsequent positive biopsy within 12 Months and 1 had CIS at 15 months F/U Yoder et al Am J Clin Path 2007: 65% of Anticipatory Positive Dx with UrCa in 29 months
21 Sarosdy et al J Urol pts with hematuria from 23 centers UrCa in 10% of pts on TURB FISH: 69% overall sensitivity (84% excluding ptag1) 65% UrCa in smokers with hematuria with positive FISH vs 24% if FISH neg STAGE
22 9q-/9p- Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% Normal Urothelium ~15% 20-30% 9q-/9p- ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis Netto, G. J. Nature Rev. Urol
23 9q-/9p- Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% FGFR3/HRAS/PIK3CA-Akt Normal Urothelium ~15% 20-30% 9q-/9p- ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis Netto, G. J. Nature Rev. Urol
24 Bladder Urothelial Carcinoma RTK-HRAS Pathway
25 Schultz L et al Cancer 2010 Chaux A et al Urology 2013
26 Bladder Urothelial Carcinoma FGFR3-HRAS Pathway FGFR3 Role in Surveillance in NMI-BC FGFR3 alone or combined with RAS and PIK3CA detect early recurrence Zuiverloon et al. Clin Cancer Res 2010 Miyaki et al. Cancer Science 2010 PCR based assays for detecting FGFR3 mutations in voided urine (45% sensitivity) Positive urine sample associated with concomitant/future recurrence in 81% (90% in patients with consecutive samples) Superior to cytology (78% vs. 0%)
27 Rhijn et al. Eur Urol 2010 mg1 (Pos FGFR3 mutation/mib1 normal) : favorable prognosis mg2 (Neg FGFR3 mutation/mib1 normal OR pos FGFR3 mutation/mib1 High): intermediate prognosis mg3 (Neg FGFR3 mutation/mib1 High ): poor prognosis
28 Sylvester et al. Eur Urol pts from 7 EORTC trials Predictive Model Parameters: Number of Tumors Tumor Size : 3 cm Prior Recurrence Rate: 1 Rec/yr pt CIS WHO grade
29 Rhijn et al. Eur Urol pts FGFR3 mutations related to favorable disease High MIB-1 correlated with pt1, high grade, and high EORTC risk scores EORTC risk scores independent predictors of recurrence and progression mg independent predictor of progression and DSS Adding mg to the multivariable model for progression increased predictive accuracy (74.9% to 81.7%) mg more reproducible than the pathologic grade (41 74%). mg1 (Pos FGFR3 mutation/mib1 normal) : favorable prognosis mg2 (Neg FGFR3 mutation/mib1 normal OR pos FGFR3 mutation/mib1 High): intermediate prognosis mg3 (Neg FGFR3 mutation/mib1 High ): poor prognosis
30 9q-/9p- Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% FGFR3/HRAS/PIK3CA-Akt Normal Urothelium ~15% 20-30% 9q-/9p- ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis Netto, G. J. Nature Rev. Urol
31 9q-/9p- Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% FGFR3/HRAS/PIK3CA-Akt Normal Urothelium ~15% P53,Rb 8p-,11p-,13q-,14q % 9q-/9p- ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis P53, Rb, 8p- 8p+,17p- Netto, G. J. Nature Rev. Urol
32 Superficial TCC RTK-HRAS Muscle Inv TCC p53 RB Netto, G. J. Nature Rev. Urol
33 George et al. JCO 2007 p53 gene and protein status show discordance in 35% of cases Exon 5 mutations demonstrated a wild-type protein Both p53 gene and protein status correlated with stage and outcome Combining p53 gene and protein status stratifies DFS: Wild-type gene and unaltered protein Either mutated gene or altered protein Mutated gene and altered protein BEST INTERMEDIATE WORST
34 Prognostc Biomarkers in UrCa Cooperative Effect of Cell Cycle Regulators Shariat S et al J Urol pts superficial (non muscle invasive) TURB P53,p21, prb, p27; IHC on TMA sections; 3.5 yr median F/U Alteration rates: p53 (34%) ; p21 (35%) ; RB (39%); p27(47%) Each marker significantly predicted progression Combination markers stratified pts into risk group SYNERGISTIC Increased risk of recurrence and progression with incremental number of altered markers Recurrence 0 PFS
35 Prognostc Biomarkers in UrCa Cooperative Effect of Cell Cycle Regulators Chatterjee et al JCO cystectomy P53,RB and p21 0 alteration: 23% 5 yr recurrence 1 alteration: 32% 5 yr recurrence 2 alteration: 57% 5 yr recurrence 3 alteration: 93% 5 yr recurrence p53,rb,p21
36 9q-/9p- Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% FGFR3/HRAS/PIK3CA-Akt Normal Urothelium ~15% P53,Rb 8p-,11p-,13q-,14q % 9q-/9p- ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis P53, Rb, 8p- 8p+,17p- Netto, G. J. Nature Rev. Urol
37 9q-/9p- Urothelial Hyperplasia LG URCa 70% Recurrence 70-80% FGFR3/HRAS/PIK3CA-Akt Normal Urothelium ~15% P53,Rb 8p-,11p-,13q-,14q % 9q-/9p- ~50% Dysplasia/CIS HG URCa Invasive URCa Metastasis P53, Rb, 8p- 8p+,17p- E-cad MMP, VEGF COX2 MMP9, VEGF TSP, IL8, EGFR, IMP3, LAMC2 Netto, G. J. Nature Rev. Urol
38 So Where do we stand?! Do we currently use ANY marker for PROGNOSTICATION in Bladder Cancer? Do we currently use ANY marker for THERAPY PREDICTION in Bladder Cancer?
39 Margulis et al JNCI radical cystectomy at six centers. High Ki-67 (>20%) labeling index independently associated with recurrence and DSS Addition of Ki-67 labeling index improved the accuracy of standard multivariate prediction model (by 2.9% for recurrence and 2.4% for DSS)
40 Genomics as Prognostic Tools
41 Two Genomic Circuits: FGFR3 mut/ampl; CCND1; PIK3CA mut; 9q (CDKN2A) deletions E2F3 ampl; RB1 del; PTEN del; CDKN2A; 5p gain P53/MDM2 alterations in both circuits at advanced Dz Lindgren et al. PLoS 2012
42 Lindgren et al PLoS 2012
43 Lindgren et al PLoS 2012
44 Lindgren et al PLoS 2012
45
46
47
48 Conclusions: Molecular understanding of bladder cancer oncogenesis has brought us within reach of our goals of stratifying management based on biomarkers More work remains.. Thank You!!!
49 Targeted Therapy for Bladder Ca.
50 Bladder Urothelial Carcinoma Targets of Rx Oncogenic pathways offer opportunities for targeted Rx: RTK-RAS-MAPK Angiogenesis mtor-pik3ca
51 UrCa TARGETED THERAPY Anti EGFR Randomized phase II trial Cetuximab Recombinant humanized murine monoclonal Ab Metastatic/recurrent non-resectable dz Gemcitabine & Carboplatin (GC) with or without Cetuximab Blocking extracellular EGFR domain inhibits downstream signal transduction pathway proliferation Anti-angiogenesis? Lapatinib in EGFR-positive and ERBB2-positive bladder tumor (phaseii/iii trial underway) Iyer G et al; Expert Rev in Anticancer Ther 2010 Wulfing C et al Cancer 2009
52 UrCa TARGETED THERAPY Tyrosin Kinase Inhibitors Phase II Cancer and Leukemia Group B trial (CALBG) Gefitinib: No OS or PFS advantage for GC+ Gefitinib Rx Vs GC alone Multitarget Agents: Phase II Sunitinib maintainance at MSKCC promising results Randomized trial underway Phase II Sorafenib (inhibitor RAF1, BRAF, PDGFRB, KDR, and FLT4) failed Philips GK et al Ann Oncol 2009 Bradely et al Clin Genitourin Cancer 2007
53 UrCa TARGETED THERAPY Anti Angiogenesis Bevacizumab: Recombinant humanized monoclonal anti-vegf Antibody First-line combination Rx with GC in patients with metastatic Dz Phase II study: two-thirds demonstrated objective response (14% CR) Phase III Cancer and Leukemia Group B trial (CALBG) underway Hahn et al JCO 2011 Elfiki AA et al Curr Oncol Rep 2009
54 UrCa TARGETED THERAPY mtor Inhibitors Evrolimus: Sirolimus-derived mtor inhibitor used in RCC Phase II trial underway in advanced Dz Iyer G et al; Expert Rev in Anticancer Ther 2010
55 Conclusions: Molecular understanding of Urothelial Ca oncogenesis has brought us within reach of our goals of stratifying management in Bladder Cancer pts based on biomarkers More work remains.. Thank You!!!
56
57
58 Superficial TCC RTK-HRAS Muscle Inv TCC p53 RB Netto, G. J. Nature Rev. Urol
59 Superficial UrCa Clinico-Pathologic PGx Urothelial Dysplasia * * Urothelial CIS * * * * * * O Donnell et al Sem Oncol 2007
60 Bladder Carcinoma Clinical Presentation/Evaluation 75% pts present with gross hematuria 10% with irritation symptoms: dysuria, urgency, frequency CIS Cystoscopy & TUR Bx: DX gold standard Understaging: 15-50% MP sampling Overstaging: muscularis propria vs muscularis mucosa (Large venules present in lamina propria)
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease
Update on bladder neoplasia: 2016 WHO classification and recent developments within the pathologic, molecular & clinical domains of the disease Biology of urothelial tumorigenesis: insights from genetically
More informationManagement of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D.
Management of High Grade, T1 Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationApplication of Urovision FISH testing for diagnosis of bladder cancer
Application of Urovision FISH testing for diagnosis of bladder cancer Eva M. Wojcik, MD Chair and Professor of Pathology and Urology Loyola University, Chicago, USA Bladder cancer - current status ~ 76,900
More informationACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI
USCAP GU Specialty Conference Case 3 March 2016 L. Priya Kunju, M.D. University of Michigan Health System Ann Arbor, MI University of Michigan Health System ACCME/Disclosures The USCAP requires that anyone
More informationThe Molecular Pathology of Bladder Carcinoma and Future Perspectives.
The Molecular Pathology of Bladder Carcinoma and Future Perspectives. ABSTRACT: GEORGE J. NETTO MD DEPARTMENTS OF PATHOLOGY, UROLOGY AND ONCOLOGY JOHNS HOPKINS MEDICAL INSTITUTIONS BALTIMORE, MD Molecular
More informationGUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER
GUIDELINES ON NON-MUSCLE- INVASIVE BLADDER CANCER (Limited text update December 21) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt Eur Urol 211 Apr;59(4):584-94 Introduction
More informationReviewing Immunotherapy for Bladder Carcinoma In Situ
Reviewing Immunotherapy for Bladder Carcinoma In Situ Samir Bidnur Dept of Urologic Sciences, Grand Rounds March 1 st, 2017 Checkpoint Inhibition and Bladder Cancer, an evolving story with immunotherapy
More informationNon Muscle Invasive Bladder Cancer. Primary and Recurrent TCC 4/10/2010. Two major consequences: Strategies: High-Risk NMI TCC
Intravesical Therapy 2010-When, with What, When to Stop Friday, April 9, 2010 Ralph de VereWhite, MD Director, UC Davis Cancer Center Associate Dean for Cancer Programs Professor, Department of Urolgoy
More informationIssues in the Management of High Risk Superficial Bladder Cancer
Issues in the Management of High Risk Superficial Bladder Cancer MICHAEL A.S. JEWETT DIVISION OF UROLOGY, DEPARTMENT OF SURGICAL ONCOLOGY, PRINCESS MARGARET HOSPITAL & THE UNIVERSITY OF TORONTO 1 Carcinoma
More informationDisclosures. The Importance of Pathology? Pathologic, Morphologic and Clinical Features. Pathologic Reproducibility
The Importance of Pathology? Seth P. Lerner, MD, FACS Beth and Dave Swalm Chair in Urologic Oncology Scott Department of Urology Baylor College of Medicine Support for research Disclosures Photocure, Imalux,
More informationCase Presentation 58 year old male with recent history of hematuria, for which he underwent cystoscopy. A 1.5 cm papillary tumor was found in the left lateral wall of the bladder. Pictures of case Case
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationBladder Sparing Treatment of Muscle Invasive Bladder Cancer
Bladder Sparing Treatment of Muscle Invasive Bladder Cancer Pr Alexandre de la Taille CHU Mondor, Créteil INSERMU955Eq07 adelataille@hotmail.com High-Risk Invasive and Muscle-Invasive BCa Radical cystectomy
More informationA Personal History NIH CWRU U of TN U of Miami Animal Model for Bladder Cancer Carcinogen induced FANFT Three Models Primary tumors individual tumors, simulates clinical scenario of locally advanced cancer
More informationManagement of High-Risk Non-Muscle Invasive Bladder Cancer. Seth P. Lerner, MD, FACS
Management of High-Risk Non-Muscle Invasive Bladder Cancer Seth P. Lerner, MD, FACS Professor of Urology, Beth and Dave Swalm Chair in Urologic Oncology, Scott Department of Urology, Baylor College of
More informationBLADDER CANCER EPIDEMIOLOGY
BLADDER CANCER WHAT IS NEW AND CLINICALLY RELEVANT Canadian Geese - Geist Reservoir (my backyard), Indianapolis, USA BLADDER CANCER EPIDEMIOLOGY Urinary bladder 17,960 2% Urinary bladder 4,390 1.6% Siegel
More informationControversies in the management of Non-muscle invasive bladder cancer
Controversies in the management of Non-muscle invasive bladder cancer Sia Daneshmand, MD Associate Professor of Urology (Clinical Scholar) Director of Urologic Oncology Director of Clinical Research Urologic
More informationManagement of Superficial Bladder Cancer Douglas S. Scherr, M.D.
Management of Superficial Bladder Cancer Douglas S. Scherr, M.D. Assistant Professor of Urology Clinical Director, Urologic Oncology Weill Medical College-Cornell University Estimated new cancer cases.
More informationCase 1. Receives induction BCG weekly x 6 without significant toxicity Next step should be:
Case 1 89 year old male with initial occurrence of gross hematuria Office flexible cystoscopy shows two papillary tumors with some surface necrosis Complete TURBT into muscle Florescence cysto shows two
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationUnderstanding the molecular pathogenesis and prognostics of bladder cancer: an overview
Review Article Understanding the molecular pathogenesis and prognostics of bladder cancer: an overview Ming Zhao 1, Xiang-Lei He 1, Xiao-Dong Teng 2 1 Department of Pathology, Zhejiang Provincial People
More informationStaging and Grading Last Updated Friday, 14 November 2008
Staging and Grading Last Updated Friday, 14 November 2008 There is a staging graph below Blood in the urine is the most common indication that something is wrong. Often one will experience pain or difficulty
More informationHow Many Diseases in Carcinoma in situ?
How Many Diseases in Carcinoma in situ? Eva Compérat La Pitié Salpêtrière Assistance Publique Université Pierre et Marie Curie, Paris VI Carcinogenesis of Bladder Cancer (BC) BC is a panurothelial disease
More informationThe Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
30 th Congress of the European Society of Pathology Tuesday, September 11, 2018 The Depth of Tumor Invasion is Superior to 8 th AJCC/UICC Staging System to Predict Patients Outcome in Radical Cystectomy.
More informationUrinary Bladder: WHO Classification and AJCC Staging Update 2017
Urinary Bladder: WHO Classification and AJCC Staging Update 2017 Houston Society of Clinical Pathologists 58 th Annual Spring Symposium Houston, TX April 8, 2017 Jesse K. McKenney, MD Classification
More informationUC San Francisco UC San Francisco Previously Published Works
UC San Francisco UC San Francisco Previously Published Works Title High-risk nonmuscle invasive bladder cancer: Definition and epidemiology Permalink https://escholarship.org/uc/item/11p2k07q Journal Current
More informationbreast and OVARIAN cancer
breast and OVARIAN cancer DR DAVID FENNELLY CONSULTANT MEDICAL ONCOLOGIST ST VINCENT S UNIVERSITY HOSPITAL DUBLIN HOW RELEVANT IS ONCOLOGY IN MEDICINE TODAY? Cancer is the second leading cause of death
More informationContemporary management of high-grade T1 bladder cancer Arnulf Stenzl
Contemporary management of high-grade T1 bladder cancer Arnulf Stenzl Dep. of Urology, Eberhard-Karls University, Tuebingen, Germany Treatment options in HG T1 BCa TUR-BT Primary and second resection (T0-status)
More informationBLADDER CANCER: PATIENT INFORMATION
BLADDER CANCER: PATIENT INFORMATION The bladder is the balloon like organ located in the pelvis that stores and empties urine. Urine is produced by the kidneys, is conducted to the bladder by the ureters,
More informationOral Communications & Posters
Carcinoma uroteliale: Current and future directions of treatment of Muscle-Invasive Bladder cancer/ Multimodality approach of bladder cancer Oral Communications & Posters CRISTINA MASINI Oncologia Medica
More informationDiscovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy
Discovery and Validation of Prognostic Genomic Based Signatures in High Risk Bladder Cancer Following Cystectomy Anirban P. Mitra, M.D., Ph.D. Center for Personalized Medicine University of Southern California
More informationBas W.G. van Rhijn, M.D., Ph.D., F.E.B.U.*
Urologic Oncology: Seminars and Original Investigations 30 (2012) 518 523 Seminar article Combining molecular and pathologic data to prognosticate non-muscle-invasive bladder cancer Bas W.G. van Rhijn,
More informationEAU GUIDELINES ON NON-MUSCLE INVASIVE (TaT1, CIS) BLADDER CANCER
EU GUIDELINES ON NON-MUSLE INVSIVE (TaT1, IS) LDDER NER (Limited text update March 2017) M. abjuk (hair), M. urger (Vice-hair), E. ompérat, P. Gontero,.H. Mostafid, J. Palou,.W.G. van Rhijn, M. Rouprêt,
More informationNeoplasms of the Prostate and Bladder
Neoplasms of the Prostate and Bladder 2015-2016 FCDS Educational Webcast Series Steven Peace, BS, CTR September 19, 2015 2015 Focus o Anatomy o SSS 2000 o MPH Rules o AJCC TNM 1 CDC & Florida DOH Attribution
More informationUpdates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency
Updates in Urologic Pathology WHO Made Those Changes?! Peyman Tavassoli Pathology Department BC Cancer Agency World Health Organization Available in Feb 2016 Frame work for reporting Major contributing
More informationNon-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience. Paul Gellhaus Assistant Clinical Professor
Non-Muscle Invasive Bladder Cancer BCG Failures: University of Iowa Hospitals and Clinics Experience Paul Gellhaus Assistant Clinical Professor Iowa??? none Disclosures Caveats Dr. Michael O Donnell
More informationWhen to Integrate Surgery for Metatstatic Urothelial Cancers
When to Integrate Surgery for Metatstatic Urothelial Cancers Wade J. Sexton, M.D. Senior Member and Professor Department of Genitourinary Oncology Moffitt Cancer Center Case Presentation #1 67 yo male
More informationJoseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016
BLADDER CANCER Joseph H. Williams, MD Idaho Urologic Institute St. Alphonsus Regional Medical Center September 22, 2016 BLADDER CANCER = UROTHELIAL CANCER Antiquated term is Transitional Cell Carcinoma
More informationIntravesical Therapy for Bladder Cancer
Intravesical Therapy for Bladder Cancer Alexandre R. Zlotta, MD, PhD, FRCSC Professor, Department of Surgery (Urology), University of Toronto Director, Uro-Oncology, Mount Sinai Hospital Director, Uro-Oncology
More informationTriple Negative Breast Cancer. Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008
Triple Negative Breast Cancer Eric P. Winer, MD Dana-Farber Cancer Institute Harvard Medical School Boston, MA October, 2008 Triple Negative Breast Cancer 15% 25% Triple Negative 20% HER2+ ER+ Low Grade
More informationA patient with recurrent bladder cancer presents with the following history:
MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationHey Doc, there s blood in my urine Evaluation of hematuria. Christian S. Kuhr, MD FACS May 4, 2018
Hey Doc, there s blood in my urine Evaluation of hematuria Christian S. Kuhr, MD FACS May 4, 2018 Objectives Understand the algorithm for hematuria evaluation Know the differential diagnosis for hematuria
More informationBreast Cancer: ASCO Poster Review
Breast Cancer: ASCO Poster Review Carmen Criscitiello, MD, PhD Istituto Europeo di Oncologia Milano HER2+ SUBTYPE Research questions in early HER2+ BC De-escalation of toxicity without compromising efficacy
More informationNon Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק
Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק 26.06.09 Lecture outlines WHO histological classification Macro/Micro assessment Early diagnosis Minimal pathology Main subtypes SCC, AdCa, LCLC
More informationQ&A. Fabulous Prizes. Collecting Cancer Data: Bladder, Renal Pelvis, and Ureter 5/2/13. NAACCR Webinar Series
Collecting Cancer Data Bladder & Renal Pelvis NAACCR 2012 2013 Webinar Series Q&A Please submit all questions concerning webinar content through the Q&A panel. Reminder: If you have participants watching
More informationNMIBC. Piotr Jarzemski. Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland
NMIBC Piotr Jarzemski Department of Urology Jan Biziel University Hospital Bydgoszcz, Poland 71 year old male patient was admitted to the Department of Urology First TURBT - 2 months prior to the hospitalisation.
More informationThe Clinical Impact of the Classification of Carcinoma In Situ on Tumor Recurrence and their Clinical Course in Patients with Bladder Tumor
Original Article Japanese Journal of Clinical Oncology Advance Access published December 17, 2010 Jpn J Clin Oncol 2010 doi:10.1093/jjco/hyq228 The Clinical Impact of the Classification of Carcinoma In
More informationT1HG Bladder Cancer What is the Best Therapy?
T1HG Bladder Cancer What is the Best Therapy? Ashish M. Kamat, MD, MBBS, FACS Professor of Urology Director, Urologic Oncology Fellowship Guidelines for T1HG Bladder Cancer AUA Recommendation: BCG induction
More informationIvyspring International Publisher. Introduction. Journal of Cancer 2017, Vol. 8. Abstract
2885 Ivyspring International Publisher Research Paper Journal of Cancer 2017; 8(15): 2885-2891. doi: 10.7150/jca.20003 Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) After Initial TUR-BT:
More information10/23/2012 CASE STUDIES: RENAL AND UROLOGIC IMPAIRMENTS. 1) Are there any clues from this history that suggest a particular diagnosis?
Case # 1 An underwriter enters your office, hands you a sheet of paper, and asks What do you think? Can we make an offer? You look at the paper and see it s lab results on a 60 year male looking for $500,000
More informationOptimal sequencing in treatment muscle invasive bladder cancer : oncologists. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Optimal sequencing in treatment muscle invasive bladder cancer : oncologists Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University Slide 2 Presented By Andrea Apolo at 2018 Genitourinary Cancers
More informationKRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS
UNIVERSITÀ DEGLI STUDI DI PALERMO Scuola di Specializzazione in Biochimica Clinica Direttore Prof. Marcello Ciaccio KRAS: ONE ACTOR, MANY POTENTIAL ROLES IN DIAGNOSIS Loredana Bruno KRAS gene Proto-oncogene
More informationShould the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer
Should the primary be treated in patients with metastatic disease? Upper Tract Urothelial Cancer Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology
More informationDisclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
More informationUrinary Cytology. Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland
Urinary Cytology Spasenija Savic Prince Pathology, University Hospital Basel, Switzerland Outline Pre-analytics The Paris System (TPS): Background Diagnostic categories Morphologic criteria for each category
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationUpdate on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual
Update on Bladder Cancer: What s New in the 2016 WHO Classification of Bladder Tumors and 8 th Edition of AJCC Staging Manual Rajal B. Shah, M.D. Director, Urologic Pathology SHAHR6@ccf.org @rajalbshah
More informationPathologic Assessment of Invasion in TUR Specimens. A. Lopez-Beltran. T1 (ct1)
Pathologic Assessment of Invasion in TUR Specimens A. Lopez-Beltran T1 (ct1) 1 Prognostic factors for progression/invasive disease Ta,T1,CIS- NMIBC :TNM 2017 ESSENTIAL: Grade T stage CIS Number of lesions
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationEGFR: fundamenteel en klinisch
EGFR: fundamenteel en klinisch Guido Lammering MAASTRO Clinic Maastricht, NL What is EGFR?? The EGFR some facts 1186 amino acids 170 kda Expressed by all cells of epithelial origin Increased activation
More informationRationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm
Rationale of The Paris System for Reporting Urinary Cytopathology: The NEW paradigm Eva M. Wojcik, MD Professor and Chair of Pathology Professor of Urology Loyola University, Chicago, Il Why to standardize
More informationClinical significance of immediate urine cytology after transurethral resection of bladder tumor in patients with non-muscle invasive bladder cancer
International Journal of Urology (2011) 18, 439 443 doi: 10.1111/j.1442-2042.2011.02766.x Original Article: Clinical Investigationiju_2766 439..443 Clinical significance of immediate urine cytology after
More informationEfficient and Effective Use of Exfoliative Markers
Innovations in Urologic Oncology: Bladder Cancer Efficient and Effective Use of Exfoliative Markers Jared M Whitson, MD April 9 th, 2010, CA URINARY TUMOR MARKERS Future Directions Urinary Tumor Markers
More informationEarly radical cystectomy in NMIBC Marko Babjuk
Early radical cystectomy in NMIBC Marko Babjuk Dept. of Urology, 2nd Faculty of Medicine, Hospital Motol, Praha, Czech Republic We Are The European Association of Urology We Are Urologists, residents,
More informationJesse K. McKenney, MD
Jesse K. McKenney, MD Outline Microscopic anatomy of the urinary bladder Diagnosing invasion Subtle patterns (variants) of carcinoma Clinically important variants of carcinoma Microanatomy of Bladder Initial
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationUrinary Bladder Cancer
Fellow GU Lecture Series, 2018 Urinary Bladder Cancer Asit Paul, MD, PhD 01/31/2018 Overview Non-muscle invasive bladder cancer Muscle invasive bladder cancer Bladder sparing chemo-radiation therapy T4b
More informationBladder Cancer Guidelines
Bladder Cancer Guidelines Agreed by Urology CSG: October 2011 Review Date: September 2013 Bladder Cancer 1. Referral Guidelines The following patients should be considered as potentially having bladder
More informationGuidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS)
Guidelines on Non-muscle invasive Bladder Cancer (TaT1 and CIS) M. Babjuk, W. Oosterlinck, R. Sylvester, E. Kaasinen, A. Böhle, J. Palou, M. Rouprêt European Association of Urology 2011 TABLE OF CONTENTS
More informationNeoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer
Neoadjuvant vs. Adjuvant Chemotherapy for Muscle-Invasive Bladder Cancer Andrew J. Stephenson, MD, FRCSC, FACS Director, Urologic Oncology Associate Professor of Surgery Glickman Urological and Kidney
More informationBreast cancer: Molecular STAGING classification and testing. Korourian A : AP,CP ; MD,PHD(Molecular medicine)
Breast cancer: Molecular STAGING classification and testing Korourian A : AP,CP ; MD,PHD(Molecular medicine) Breast Cancer Theory: Halsted Operative breast cancer is a local-regional disease The positive
More informationGuidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Bladder Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationRisk Adapted Treatment of Non-muscle Invasive Bladder Cancer. Eila C. Skinner, MD
Risk Adapted Treatment of Non-muscle Invasive Bladder Cancer Eila C. Skinner, MD Professor, Department of Urology Stanford University SWIU Winter Meeting January, 2015 Goals Minimize treatment for patients
More informationLooking Beyond the Standard-of- Care : The Clinical Trial Option
1 Looking Beyond the Standard-of- Care : The Clinical Trial Option Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program UF Health Cancer Center at Orlando Health Professor
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationIntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
More information5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.
Common Differential Diagnoses in Urological Pathology Jonathan I. Epstein Prostate Adenocarcinoma vs. Urothelial Carcinoma 1 2 NKX3.1 NKX3.1 3 4 5 6 Proposed ISUP Recommendations Option to use PSA as a
More informationTrimodality Therapy for Muscle Invasive Bladder Cancer
Trimodality Therapy for Muscle Invasive Bladder Cancer Brita Danielson, MD, FRCPC Radiation Oncologist, Cross Cancer Institute Assistant Professor, Department of Oncology University of Alberta Edmonton,
More informationBladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United
1 Chapter 1: Background 1.1 Bladder Cancer Incidence and Etiology Bladder cancer (BC) is the fifth most commonly diagnosed malignancy in the United States, with more than 70,000 new cases and more than
More informationClinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy
Jpn J Clin Oncol 2002;32(11)461 465 Clinical Study of G3 Superficial Bladder Cancer without Concomitant CIS Treated with Conservative Therapy Takashi Saika, Tomoyasu Tsushima, Yasutomo Nasu, Ryoji Arata,
More informationICUD 2011 Recommendations. Bladder Cancer
ICUD 2011 Recommendations Bladder Cancer ICUD Bladder Cancer 2011 Chair Mark Soloway Co chair Henk van der Poel Committee Chairs A. Kamat/P. Hegarty M. Amin/V. Reuter P. Karakiewicz/S. Shariat B. Konety/W.
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationChemotherapy Treatment Algorithms for Urology Cancer
Chemotherapy Treatment Algorithms for Urology Cancer Chemoradiation for bladder cancer; Chemotherapy algorithm for non TCC bladder cancer Squamous cell carcinoma; Chemotherapy Algorithm for Non Transitional
More informationAfterword: The Paris System for Reporting Urinary Cytology
Afterword: The Paris System for Reporting Urinary Cytology Dorothy L. Rosenthal, Eva M. Wojcik, and Daniel F.I. Kurtycz The primary goal of The Paris System Working Group was standardizing the terminology
More informationMEDitorial March Bladder Cancer
MEDitorial March 2010 Bladder Cancer Last month, my article addressed the issue of blood in the urine ( hematuria ). A concerning cause of hematuria is bladder cancer, a variably malignant tumor starting
More informationHER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam
HER2 status assessment in breast cancer Marc van de Vijver Academic Medical Centre (AMC), Amsterdam 13e Bossche Mamma Congres 17 th June 2015 Modern cancer therapies are based on sophisticated molecular
More informationDiagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines
Diagnosis & Treatment of Non- Muscle Invasive Bladder Cancer: AUA/SUO Guidelines Sam S. Chang, MD, MBA Patricia & Rodes Hart Chair Professor of Urologic Surgery & Oncology Vanderbilt University Medical
More informationCritical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC
Critical Evaluation of Early Post-operative Single Instillation Therapy in NMIBC Levent N. Türkeri MD, PhD Professor of Urology Acıbadem University Faculty of Medicine Istanbul Conflict of Interest No
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationCase by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1
Case by Case: Critical Issues in Superficial Bladder Cancer Management 5/24/05 13:46 1 Case Study 1 A 22-year-old man with a history of gross total painless hematuria: two times in two months, both after
More informationMETASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD
METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD INTRODUCTION Second leading cause of cancer related death in the United States. 136,830 cases in 2014
More informationChemotherapy and Bladder Cancer. Blayne Welk UBC Urology Grand Rounds June 4, 2008
Chemotherapy and Bladder Cancer Blayne Welk UBC Urology Grand Rounds June 4, 2008 Outline Review of Incidence and Impact of bladder cancer Neoadjuvant chemotherapy Adjuvant chemotherapy Bladder preservation
More informationThe pathology of bladder cancer
1 The pathology of bladder cancer Charles Jameson Introduction Carcinoma of the bladder is the seventh most common cancer worldwide [1]. It comprises 3.2% of all cancers, with an estimated 260 000 new
More informationShould We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis?
Should We Screen for Bladder Cancer in a High Risk Population: A Cost per Life-Year Saved Analysis? Yair Lotan, Robert S. Svatek, Arthur I. Sagalowsky Should We Screen? Prevalence 5 th most common cancer
More informationPanel: A Case-based Approach to the Management of Bladder Cancer
Panel: A Case-based Approach to the Management of Bladder Cancer ~ Moderator: Robert Donohue, MD Panel: David C. Beyer, MD E. David Crawford, MD Donald L. Lamm, MD Paul D. Maroni, MD TCC Cases Robert E.
More informationOld and New Radiation for Bladder and Upper Tract Cancers. Bridget Koontz Radiation Oncology Duke Cancer Institute
Old and New Radiation for Bladder and Upper Tract Cancers Bridget Koontz Radiation Oncology Duke Cancer Institute Disclosures Janssen funded clinical research BlueEarth Diagnostics advisory board member
More information